Director (OrbiMed) Purchases $5.0M in Pre-Funded Warrants
STTK has more than doubled off its 52-week low of $0.712.
Summary
A director associated with institutional investor OrbiMed Advisors purchased approximately $5.0 million in pre-funded warrants, indicating strong institutional confidence in Shattuck Labs.
Key Events · Ownership and Investor Activity · STTK
-
Significant Institutional Investment
Mona Ashiya, a director representing OrbiMed Advisors, acquired 1,250,000 pre-funded warrants for approximately $5.0 million.
-
Follows Recent Public Offering
This purchase occurred on June 11, 2026, as part of a public offering that closed on the same day, where pre-funded warrants were priced at $3.9999 each.
-
Strong Vote of Confidence
The substantial investment by a major institutional shareholder with a board seat signals strong conviction in Shattuck Labs' valuation and clinical pipeline, particularly after recent positive Phase 1 trial results for SL-325.
Analysis · STTK · Life Sciences
Mona Ashiya, a director representing OrbiMed Advisors, acquired approximately $5.0 million worth of pre-funded warrants. This significant investment by a major institutional shareholder, especially following a recent public offering and positive clinical trial results, signals strong confidence in the company's future prospects and valuation.
At the time of this filing, STTK was trading at $4.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $355M. The 52-week trading range was $0.71 to $8.33. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.